The human evidence on GHK-Cu side effects is thin in both of the ways it is sold: there are a handful of small studies of creams and serums, and almost nothing on injecting it. Topical and injected GHK-Cu are not the same exposure, because intact skin keeps most of the peptide out while a needle puts all of it, plus anything else in the vial, into the body. The FDA has said compounded injectable GHK-Cu may pose a risk of immune reactions and that there are limited human data to judge its safety.
What GHK-Cu is
GHK is a tripeptide, three amino acids long: glycyl-L-histidyl-L-lysine. It occurs naturally in human plasma, saliva and urine, and its levels fall with age. It binds copper, and the copper complex is called GHK-Cu (Pickart et al., BioMed Research International, 2015).
In laboratory and animal studies, GHK-Cu has been reported to stimulate collagen and glycosaminoglycan production, attract immune and blood-vessel cells to wounds, and speed wound healing in rats, mice, pigs and dogs. Two of the most detailed reviews of GHK were written by authors whose listed affiliation is a commercial skin-biology research and development department, which is worth knowing when you read claims that its actions “appear to be health positive” (Pickart and Margolina, International Journal of Molecular Sciences, 2018).
The evidence for GHK-Cu in skincare
Clinical evidence is much thinner than the lab work. A 2026 systematic review in Aesthetic Surgery Journal found 20 eligible studies of GHK-Cu as a standalone aesthetic treatment; 18 were preclinical and only 2 were randomized controlled trials. The authors said the findings were constrained by methodological variability and a limited number of well-designed clinical trials (Mokhtar et al., Aesthetic Surgery Journal, 2026).
The two trials point in different directions. The review reports that GHK-Cu significantly reduced wrinkle volume and depth compared with controls in one of them. The other shows how small the evidence base is. Thirteen patients who had carbon dioxide laser resurfacing around the mouth were randomized to aftercare with or without GHK-Cu products. Computer analysis and blinded evaluators found no significant difference in how fast redness resolved, and no objective difference in wrinkles or overall skin quality. Patients using GHK-Cu did report higher satisfaction (Miller et al., Archives of Facial Plastic Surgery, 2006).
A separate 2026 review in Pharmaceutics concluded that clinical evidence remains sparse, that older cosmetic reports are small or incompletely characterized, and that GHK-Cu should be regarded as “promising but unproven” rather than a clinically validated regenerative drug. It noted that a phase 2 wound-healing trial (NCT07437586) was still recruiting with no efficacy results (Mateescu et al., Pharmaceutics, 2026).
📨 Get Free Peptide Risk Guides Alerts
Free · No spam · Unsubscribe anytime
Skincare is regulated as cosmetics. The FDA says cosmetic products and ingredients, other than color additives, do not need FDA approval before they go on sale. A product intended to affect the structure or function of the body is legally a drug, even if it also changes appearance, so the claims made for a product determine how it is regulated (FDA, FDA Authority Over Cosmetics).
Why topical results say nothing about injection
The outer layer of skin is a strong barrier, especially for water-loving molecules like GHK-Cu. In a laboratory test on human skin, almost no peptide or copper passed through intact skin over nine hours; only after the skin was pre-treated with microneedles did meaningful amounts cross (Li et al., Pharmaceutical Research, 2015). An earlier test on thinner, dermatomed human skin did find copper from GHK-Cu moving into and through the tissue (Hostynek et al., Inflammation Research, 2010). The two methods differ, but both describe a barrier that limits and slows exposure.
An injection removes that barrier. Everything in the vial reaches living tissue at once, which changes the safety question in several ways:
- Immune reactions. The FDA says compounded injectable GHK-Cu may pose a risk of immunogenicity because of aggregation and peptide-related impurities, and that limited human data exist to inform safety (FDA, bulk drug substances that may present significant safety risks).
- Sterility and endotoxin. A serum does not need to be sterile; an injection does. Non-sterile vials can cause abscesses and other infections, covered in injection-site infections and abscesses.
- Copper. The Pharmaceutics review found that GHK-Cu products and studies usually do not report how much of the copper is free (labile) rather than bound, even though toxicity can depend on it.
- Content. Vials sold as research chemicals are not checked against a label claim by any regulator. See what “research use only” means and what a certificate of analysis can prove.
The regulatory history reflects this split. The FDA listed GHK-Cu “for injectable routes of administration” in category 2, its list of bulk substances for compounding that may present significant safety risks, and later moved it to a list of substances whose nominations were withdrawn by the nominators. The FDA page, current as of April 22, 2026, does not describe its present status beyond that. How compounding categories work is explained in Are Peptides Legal?
Topical and injected GHK-Cu side by side
| Skincare (cream, serum) | Injectable vial | |
|---|---|---|
| How it is regulated | Cosmetic; no FDA approval needed before sale | Listed by FDA as a compounding safety concern; nomination later withdrawn |
| Human evidence | A few small trials; 2 randomized trials in a 2026 review | FDA: limited human data on safety |
| Exposure | Limited by the skin barrier | Full contents delivered under the skin |
| Main known concerns | Skin irritation, as with any cosmetic ingredient | Immune reactions, impurities, infection, unknown copper load |
| Premarket review | None by FDA | None by FDA, if sold as a research chemical |
Who should be especially cautious about extra copper
Copper is an essential nutrient, but the body has to control how much it holds. In Wilson disease, an inherited condition, copper builds up to toxic levels that can damage tissues and organs, particularly the liver and brain (MedlinePlus Genetics, Wilson disease). We found no human study measuring what repeated injection of GHK-Cu does to copper levels in the body, in people with or without a copper-handling disorder. If you have Wilson disease or liver disease, that unanswered question matters more, and a hepatologist is the right person to ask.
GHK-Cu side effects: what to watch for
- From skincare: redness, stinging, itching or a rash where the product was applied. A rash that persists or spreads is worth showing to a dermatologist; bring the product’s ingredient list.
- From an injection, same day: spreading redness, heat, swelling or severe pain at the site, or fever.
- From an injection, emergency: hives with swelling of the lips, face or throat, wheezing or trouble breathing, or feeling faint. These are signs of a severe allergic reaction.
- Later: lumps or sores at injection sites that do not heal.
When marketing cites “clinical studies” of copper peptides, it is worth knowing their size: in the laser-resurfacing trial, 13 patients completed the study and blinded measurements found no difference in redness or wrinkles, and no published trial has tested injected GHK-Cu for safety in people.
Sources
- U.S. Food and Drug Administration: Certain bulk drug substances for use in compounding that may present significant safety risks
- U.S. Food and Drug Administration: FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated
- NIH National Library of Medicine, MedlinePlus Genetics: Wilson disease
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int, 2015.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018.
- Mokhtar J et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J, 2026.
- Mateescu DM et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo. Pharmaceutics, 2026.
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006.
- Li H et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res, 2015.
- Hostynek JJ et al. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer. Inflamm Res, 2010.